Connect
MJA
MJA

Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association

Stephen M Twigg, Maarten C Kamp, Timothy M Davis, Elizabeth K Neylon and Jeffrey R Flack
Med J Aust 2007; 186 (9): 461-465.
  • Stephen M Twigg1,2
  • Maarten C Kamp3,4
  • Timothy M Davis5,6
  • Elizabeth K Neylon7
  • Jeffrey R Flack8,9

  • 1 Department of Medicine, University of Sydney, Sydney, NSW.
  • 2 Royal Prince Alfred Hospital, Sydney, NSW.
  • 3 Gold Coast Hospital, Gold Coast, QLD.
  • 4 Griffith University, Brisbane, QLD.
  • 5 Fremantle Hospital, Fremantle, WA.
  • 6 School of Medicine and Pharmacology, University of Western Australia, Fremantle, WA.
  • 7 South Metropolitan Health Service Area, Department of Health, Perth, WA.
  • 8 Diabetes Centre, Bankstown–Lidcombe Hospital, Sydney, NSW.
  • 9 University of New South Wales, Sydney, NSW.

Correspondence: stwigg@med.usyd.edu.au

Acknowledgements: 

We thank the Project Officer, Dr Abdullah Omari (ADS paid consultant), and the ADS Council members who were not part of the Prediabetes Working Party for their contribution: Dr Wah Cheung, Dr Alicia Jenkins, Professor Mark Febbraio, Dr Terri Allen, and Associate Professor Glenn Ward. The ADS members who commented on the draft statement are also recognised, as is the contribution of the ADEA Board, especially Ms Shirley Cornelius. Assistance from ADS Secretary, Ms Suzie Neylon, and the Executive Officer of the Australian Diabetes Professional Organisations, Mr Chris Thorpe, is acknowledged with thanks.

Competing interests:

Stephen Twigg has received speaker fees for educational meetings in diabetes, from Alphapharm, Eli Lilly, GlaxoSmithKline, Novo Nordisk, Sanofi-aventis and Servier.

  • 1. National Health and Medical Research Council. A guide to the development, implementation and evaluation of clinical practice guidelines. Canberra: NHMRC, 1999.
  • 2. US Department of Health and Human Services, American Diabetes Association. HHS, ADA warn Americans of “pre-diabetes”. Press release. 27 Mar 2002. Washington, DC: DHHS, 2002. http://www.hhs.gov/news/press/2002pres/20020327.html (accessed Mar 2007).
  • 3. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005; 28 Suppl 1: S4-S36.
  • 4. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva: WHO, 1999. http://www.diabetes.com.au/pdf/who_report.pdf (accessed Mar 2007).
  • 5. Genuth S, Alberti KG, Bennett P, et al; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167.
  • 6. Vaccaro O, Riccardi G. Changing the definition of impaired fasting glucose: impact on the classification of individuals and risk definition. Diabetes Care 2005; 28: 1786-1788.
  • 7. Dunstan DW, Zimmet PZ, Welborn TA, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002; 25: 829-834.
  • 8. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006; 29: 1130-1139.
  • 9. Piche ME, Despres JP, Pascot A, et al. Impaired fasting glucose vs. glucose intolerance in pre-menopausal women: distinct metabolic entities and cardiovascular disease risk? Diabetic Med 2004; 21: 730-737.
  • 10. Henry P, Thomas F, Benetos A, et al. Impaired fasting glucose, blood pressure and cardiovascular disease mortality. Hypertension 2002; 40: 458-463.
  • 11. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004; 27 Suppl 1: S11-S14.
  • 12. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
  • 13. Zhang P, Engelgau MM, Valdez R, et al. Costs of screening for pre-diabetes among US adults: a comparison of different screening strategies. Diabetes Care 2003; 26: 2536-2542.
  • 14. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
  • 15. Tuomilehto J, Lindstrom J, Eriksson JG, et al; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
  • 16. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537-544.
  • 17. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002; 19: 708-723.
  • 18. Shaw JE, Zimmet PZ, de Courten M, et al. Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? Diabetes Care 1999; 22: 399-402.
  • 19. Decode Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.
  • 20. Coutinho M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233-240.
  • 21. Liao D, Shofer JB, Boyko EJ, et al. Abnormal glucose tolerance and increased risk for cardiovascular disease in Japanese-Americans with normal fasting glucose. Diabetes Care 2001; 24: 39-44.
  • 22. Bjornholt JV, Erikssen G, Aaser E, et al. Fasting blood glucose: an underestimated risk factor for cardiovascular death. Results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care 1999; 22: 45-49.
  • 23. Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998; 140: 199-270.
  • 24. Lempiainen P, Mykkanen L, Pyorala K, et al. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 1999; 100: 123-128.
  • 25. Laaksonen DE, Lakka HM, Niskanen LK, et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002; 156: 1070-1077.
  • 26. Alberti K, Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
  • 27. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
  • 28. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Taskforce Consensus Group. The metabolic syndrome — a new worldwide definition. Lancet 2005; 366: 1059-1062.
  • 29. Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 2005; 67: 152-162.
  • 30. Ramachandran A, Snehalatha C, Mary S, et al; Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006; 49: 289-297.
  • 31. Sheard NF, Clark NG, Brand-Miller JC, et al. Dietary carbohydrate (amount and type) in the prevention and management of diabetes: a statement by the American Diabetes Association. Diabetes Care 2004; 27: 2266-2271.
  • 32. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005; 143: 251-264.
  • 33. Lindstrom J, Louheranta A, Mannelin M, et al. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003; 26: 3230-3236.
  • 34. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-2077.
  • 35. Van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst Rev 2006; (4): CD005061.
  • 36. Snitker S, Watanabe RM, Ani I, et al. Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. Diabetes Care 2004; 27: 1365-1368.
  • 37. Gerstein HC, Yusuf S, Bosch J, et al; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-1105.
  • 38. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. [Erratum appears in Diabetes Care 2004; 27: 856.] Diabetes Care 2004; 27: 155-161.
  • 39. Chobanian AV, Bakris GL, Black HR, et al; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
  • 40. National Heart Foundation of Australia; Cardiac Society of Australia and New Zealand. Lipid management guidelines — 2001. Med J Aust 2001; 175 (9 Suppl): S57-S85. http://www.heartfoundation.com.au/downloads/Guideline_Lipid_Mgt_2001.pdf (accessed Mar 2007).
  • 41. American Diabetes Association. Standards of medical care in diabetes — 2007. Diabetes Care 2007; 30 Suppl 1: S4-S41.
  • 42. American Diabetes Association. Self-monitoring of blood glucose. Diabetes Care 1994; 17: 81-86.
  • 43. Gabir MM, Hanson RL, Dabelea D, et al. Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. Diabetes Care 2000; 23: 1113-1118.
  • 44. Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 2001; 24: 1448-1453.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.